# OnCo record cadance-304 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/cadance-304/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "cadance-304" ;
  schema:name "CaDAnCe-304"@en ;
  schema:description "CaDAnCe-304 is the first phase 3 of a protein degrader in leukaemia, pitting BTK destruction against the best available BTK inhibitor."@en ;
  schema:url <https://onco.cc/trials/cadance-304/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://ashpublications.org/blood/article/146/Supplement%201/5691/550156/CaDAnCe-304-a-phase-3-open-label-randomized-study> ;
  onco:status "recruiting" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/cll/> ;
  onco:technologies <https://onco.cc/technologies/protac-degrader/> ;
  onco:targets <https://onco.cc/targets/btk/> ;
  onco:drugs <https://onco.cc/drugs/bgb-16673/>, <https://onco.cc/drugs/pirtobrutinib/> ;
  onco:companies <https://onco.cc/companies/beone/> .